Drug Trial Radar · NCT07811518
Latent Infection Freshmen Tracking for Tuberculosis
Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,000
Planned (sponsor's estimate)
Start
Aug 15, 2022
Primary completion
Aug 31, 2026
Study completion Aug 31, 2029
Sponsor
- Lead sponsor
- Affiliated Hospital of Nantong UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Meishan Municipal Center for Disease Prevention and Control
- First posted
- Sep 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 14 years, up to 24 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this study is to learn whether taking short-course preventive treatment in high school and college freshmen with strong positive tuberculosis (TB) skin tests can safely and effectively protect them from developing active TB over a 3-to-4-years period. Main question: Does taking short-course preventive treatment reduce the risk of active TB in freshmen who have strong positive TB skin tests? All freshmen across 26 schools in Meishan City, Sichuan Province, China were screened for TB. Among them, the students with strong positive skin tests (indicating latent TB infection) and no active disease entered the study. Students voluntarily chose to either take a 3-month short-course preventive treatment under campus medical supervision or receive routine health observation without medication. Researchers tracked all participants for 3 to 4 years to monitor who developed active TB and evaluate the treatment's safety and effectiveness.
Conditions
- Latent Tuberculosis Infection (LTBI)
- Tuberculosis (TB)
Interventions
tuberculosis preventive treatmentDrug
3HR Regimen: Isoniazid (INH) + Rifampin (RIF), once daily, 90 total doses (3 months); 3H2P2 Regimen: Isoniazid (INH) + Rifapentine (RPT), twice weekly, 24 total doses (3 months)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incident active tuberculosisTime frame: Up to 4 years post-baseline screening (from T0 through August 31, 2026)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China · Recruiting
Meishan Municipal Center for Disease Prevention and Control
Meishan, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.